BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer

The aim of this study was to focus on clinicopathological characteristics and prognosis in men with prostate cancer (PCa) harboring a breast cancer 2 (BRCA2) gene mutation and to offer convincing evidence to consider BRCA2 mutation as a marker of poor prognosis in the molecular classification of PCa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Ming, Gao, Xian-Shu, Gu, Xiaobin, Guo, Wei, Li, Xiaoying, Ma, Mingwei, Qin, Shangbin, Qi, Xin, Xie, Mu, Peng, Chuan, Bai, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522317/
https://www.ncbi.nlm.nih.gov/pubmed/28410213
http://dx.doi.org/10.18632/oncotarget.16712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522317/
https://www.ncbi.nlm.nih.gov/pubmed/28410213
http://dx.doi.org/10.18632/oncotarget.16712

Ejemplares similares